Back HIV Treatment Search for a Cure

Search for a Cure

AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function

A group of youngSouth African women who were diagnosed during very HIV early infection and immediately given antiretroviral therapy (ART) preserved their CD4 cell counts and the function of cells that HIV normally disrupts, according to a study presented at the 2016 Towards an HIV Cure Symposium, which preceded the 21st International AIDS Conference this week in Durban, South Africa. The majority of them never seroconverted, staying HIV-negative despite having evidence of low levels of HIV infection in their cells.

alt

Read more:

amfAR Announces New Round of HIV Cure Research Grants

This month amfAR, the Foundation for AIDS Research, announced that it has granted 7 awards for research on HIV persistence, the understanding of which could lead to new approaches to an HIV cure -- part of the organization's Countdown to a Cure for AIDS initiative.

alt

Read more:

CROI 2016: VRC01 Antibody Delays But Does Not Prevent HIV Rebound After ART Interruption

VRC01, a broadly neutralizing antibody targeting HIV's CD4 binding site, was able to modestly delay the return of viral replication following interruption of antiviral therapy (ART), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. VRC01 did not maintain viral suppression on its own, but it may play a role in combination therapy for HIV treatment or a functional cure.

alt

Read more:

Gene Therapy Snips HIV Out of Infected Cells and Makes Uninfected Cells Resistant

For the first time, researchers have used a gene-editing technique related to one already used to produce cells resistant to HIV infection to target HIV-infected cells. They have managed to remove HIV genes completely from infected cells, as shown by reductions in the cells' overall rate of HIV production. In cells not already infected, the therapy has itself become part of their genome, producing cells that are resistant to infection for a prolonged period, according to a report in a recent edition of Nature Scientific Reports.

alt

Read more:

CROI 2016: Dose-Finding Trials of Antibody-Based Drugs for HIV Prevention To Start Soon

The next generation of pre-exposure prophylaxis (PrEP), and even HIV treatment, may consist of antibodies that could be given as an intravenous infusion or an injection into muscle, according to 2 presenters at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

Read more: